Exploring MDMA-Assisted Therapy for Trauma Care in Israel

In the aftermath of the October 7 Hamas-led massacre and the subsequent war, approximately 3 million adults in Israel are experiencing anxiety, depression, or symptoms of post-traumatic stress disorder (PTSD). With mental health services overwhelmed, a new study aims to test MDMA-assisted psychotherapy in a group setting, potentially addressing the urgent demand for trauma care. This study, led by MAPS Israel, is the first of its kind globally to explore MDMA use in a postwar group therapy model.

The Media Line

The MDMA-assisted psychotherapy study will involve group therapy sessions, where two therapists will treat a group of eight participants, significantly increasing the number of individuals who can receive care. Eyal Gura, a venture capitalist and co-initiator of the study, emphasized the need for scalable solutions given the shortage of trained therapists. The trial, conducted in partnership with Sheba Medical Center, is expected to begin by the end of 2023, initially enrolling 20 participants, followed by 168 in subsequent phases, making it the largest clinical trial of its kind in Israel.

The Media Line

Participants will include individuals affected by the recent conflict, such as Israel Defense Forces veterans and residents of communities near Gaza. The study aims to provide insights into the efficacy of MDMA in treating collective trauma, which Tzarfaty, co-founder of MAPS Israel, describes as a pressing issue for those who have experienced similar traumatic events.

The Media Line

While MDMA is not yet approved by the U.S. Food and Drug Administration (FDA) for PTSD treatment, Australia has recently approved its use for treatment-resistant PTSD. The FDA has called for further research, and Tzarfaty hopes that the Israeli study will contribute valuable data to support future regulatory decisions. Israeli psychiatrist Oded Arbel noted that other psychedelics, such as ketamine and psilocybin, also show promise in treating trauma-related conditions, underscoring the need for responsible administration by qualified professionals.

The Media Line

Despite the potential benefits, there are concerns regarding the safety and efficacy of psychedelic-assisted therapies. Critics argue that more comprehensive data is needed before widespread implementation. Additionally, the stigma surrounding psychedelics, rooted in historical contexts, may hinder acceptance and regulatory approval. Gura acknowledged this challenge but expressed optimism that scientific evidence could shift perceptions.

The Media Line

If successful, the MDMA protocol could serve as a model for addressing collective trauma not only in Israel but also in other regions facing similar challenges, such as Ukraine. Tzarfaty emphasized the importance of unifying efforts to disseminate information about trauma treatment, stating, “For collective trauma, we need to bring collective treatment.” The outcomes of this study may pave the way for innovative mental health solutions that could transform care for trauma survivors globally.

The Media Line

“Instead of two therapists treating one person, which is the current MDMA research protocol, in the new study, we’re doing two therapists treating a group of eight people.” — Eyal Gura, Co-Initiator of the Study

The Media Line

“Trauma impacts all layers of society. For collective trauma, we need to bring collective treatment.” — Dr. Keren Tzarfaty, Co-Founder of MAPS Israel

The Media Line

“People are suffering from trauma all over Israel and all over the world,” — Oded Arbel, Psychiatrist

The Media Line

“Everything we do is purely scientific, and with the results, we hope that people will be convinced,” — Eyal Gura, Co-Initiator of the Study

The Media Line